However, as a safety measure, patients with profound coagulopathy (defined by > 2.5 times normal prothrombin time, > 2 times normal APTT, platelet count ≤ 50 or on IV heparin infusion APTR ≥ 2) will not be recruited or studied if this occurs. The gene discussed is F2; the disease is blood coagulation disease.